Agenda
13-16 October 2025
RAI Congress Centre, Amsterdam
Barcelona, 28 - 31 October 2024
Schedule
Create your personal agenda –check the favourite icon
Platform Technologies Workshop [AM1]
Biothreats & Disease X Workshop [AM2]
Mucosal & Alternative Delivery Workshop [PM1]
Vaccine Equity Workshop [PM2]
Create your personal agenda –check the favourite icon
Strengthening Global Preparedness and Building Resilient Health Systems: Meeting Pandemic and Epidemic Demands
-Overview of international cooperation frameworks for pandemic preparedness and response
-Assessing needs for further developments in global regulatory oversight
-Strategies for building flexible and resilient health systems
-Building global capacity to meet emerging demands; leveraging lessons from mpox to enhance preparedness
Strategies for Achieving Global Immunization Equity: How Soon Can We Make It a Reality?
- Overview of global efforts to address inequities in distribution and access
- Local production, equitable distribution?
- Market shaping and health financing
- Impact of vaccination on infectious disease epidemiology
- How can we strategically align approaches with specific country requirements and adapt them to diverse disease landscapes for equitable outcomes?
- Is the global vaccine pipeline in development aligned with local and regional disease priorities to address immunization equity? How important is end to end R&D and manufacturing capacity in LMICs to achieve global immunization?
Morning Exhibition & Networking Break
Join us in the exhibition hall for:1-2-1 partnering, refreshments
A Decade of Advancements: Electronic Tools Revolutionizing Vaccine Clinical Trial Operations
Adoption and utilization of virus neutralization assays: Challenges and best practices
Driving equity, diversity and inclusivity into vaccine research: a framework for delivering differently
How to generate regulatory grade RWE for vaccines
Impact of new technologies enabling rapid protein vaccine development
Unique considerations for conducting paediatric vaccine trials
Expo & Networking Break
Join us in the exhibition hall for:1-2-1 partnering, refreshments, start-up pitches & poster sessions
Start-up Pitches
12:20 Lovaltech: Beyond vaccination: exploiting the nasal route for optimal mucosal defense strategies - Serge Pampfer
12:25 Idevax: Resolving Skin Drug Delivery Challenges - Vanessa Vankerckhoven
12:30 bespark*bio: bespark*bio - the evolution of process development - Matthias Müllner
12:35 Meclinas: Meclinas, an Independant Clinical Trial Site - Ine Vercammen
12:40 Jurata Thin Film: Novel Formulations Eliminate Cold Chain and Enable Needle-Free Vaccine Administration - Megan Livingston
12:45 C-Cube: How to build a modular vaccine facility within 12 months – a case study - Thomas Hauser
12:50 KyooBe Tech: eFit - using low electron energy to make a difference Martina Hampel
12:55 Orlance MACH-1 Vaccines Deliver Optimal T-Cell and Mucosal Immunity – Kristyn Alto
13:00 Psyon Games: The future of health games – Olli Rundgren
13:05 VPUbio: Performance in Pseudotyping – Nigel Temperton
13:10: Cocoon Bioscience: CrisBio®: A novel, natural and scalable protein expression system – Maite Segurola
Poster Presentations
Deadline for poster abstract submission: Monday 7th October 2024
Capillary Devices for Sample Collection in Decentralized Vaccine Studies
COVID & Beyond Track Chair
Alternatives to Animal Models: Current Progress and Future Goals
- Current landscape: overview of emerging alternative approaches, what programmes & strategies are being put in place to adopt alternative approaches to animal use?
- Strategies for integrating these approaches and assessing the reliability and validity of the data obtained; how is this data going to be used to understand disease at the level of R&D?
- Exploring the regulatory framework
- Collaborative efforts and knowledge sharing
- Challenges and future directions for accelerating the adoption of alternative methods
Pre-Clinical Development Track Chair
Correlates of protection in the CoV002 trial of ChAdOx1.nCOV19 (Vaxzevria): A Systems Serology analysis
Immune Profiling Track Chair
New tricks for 190 kb of genomic DNA in the cytoplasm: MVA as a viral vector for Personalized Vaccines and Pandemic Response.
Technology Showcases Track Chair
Formulation & Bioprocess Track Chair
Improving Performance of Vaccines with Needle-free Technology
AMR & Bacterial Vaccines Track Chair
WHO Full Value of Vaccines Study
Accelerate and simplify mRNA CQA testing: a novel strategy for rapid measurement of capped mRNA integrity and 5’ capping efficiency
Ensuring clinical availability of vaccine delivery systems, immunostimulators & combined adjuvant systems
Optimized Prime: A Transformative RNA-LNP Vaccine Composition that Scales
Current challenges in biological standardisation of Serum Bactericidal Assay (SBA)
Characterizing vaccine-induced immune responses with ELISpot and FluoroSpot assays
Capturing high quality immunoassay data- case studies using Certimmune
A new animal-free recombinant enzyme for cell-based vaccine production
The use of high-performing raw materials is crucial for ensuring safe and efficient manufacturing of vaccines. Trypsin is a fundamental material in cell-based vaccine production facilitating virus expansion as well as playing an important role in activating specific virus particles including influenza. Despite rigorous testing of raw materials, the use of animal-derived trypsin carries the risk of introducing adventitious contaminants, and infection of cell cultures has potentially serious consequences for patients and production continuity. The new enzyme TrypsiNNex® addresses safety and consistency concerns. TrypsiNNex® is high-purity, recombinantly produced, animal-free trypsin, enabling a more robust production and reducing the risk for contamination.A controlled production process ensures TrypsiNNex® is being expressed and maintained in an inactive form until stabilization resulting in a high and consistent proportion of β-trypsin. This makes it ideal for virus-vaccine production. In this presentation, we will show how TrypsiNNex® can optimize the production of influenza vaccines.
Demonstrating value and introducing ‘vaccines against AMR’ into policy framework
- How are we considering the evidence of the value of vaccines against AMR in vaccine recommendations?
- What additional evidence is needed to inform policy and regulatory changes?
- The impact of viral vaccines on antibiotic usage and AMR incidence, how are we measuring this?
Developing sample-saving multi-pathogen multiplex immunoassays to assess humoral immune responses
Navigating The Future of Vaccine Manufacturing with Molecular Devices
COVID-19 protein vaccines: A race to cope with a continuous evolving virus.
Developmental and Reproduction Toxicity (DART) Assessment for VACCINES
Human in vitro modeling for age-specific adjuvanted vaccine discovery and development
Advanced Technologies in Animal-Free Viral Vaccines Production
Expanding the availability of emulsion adjuvants via synthetic biology
Immunoprofiling approaches to accelerate adjuvanted vaccine design
Immunoprofiling is essential for accelerating adjuvanted vaccine design by providing a detailed understanding of immune responses at the cellular and molecular levels, enabling more precise matching of vaccine formulations to target pathogens and populations. In this talk, we will present two key immunoprofiling approaches for vaccine development. First, we explore how exploratory clinical studies incorporating multiple tertiary immunoprofiling endpoints can guide vaccine formulation selection in early clinical phases. Second, we present data from an ex vivo human lymph node culture model that recapitulates key mechanisms of action of the AS01 adjuvant, demonstrating the potential of in vitro models to replicate vaccine effects observed in humans. Together, these findings underscore the opportunities to accelerate adjuvanted vaccine design through advanced immunoprofiling techniques
A scalable cell-free protein production technology accelerating vaccine development
The emergence of scalable eukaryotic cell-free protein expression disrupts the current paradigm of protein production by removing cell engineering as a significant speed-limiting step. With ready-to-use cell-free lysates, protein expression from a gene of interest (via DNA template) to purified protein can now be achieved within 4-6 weeks, regardless of scale.
The ALiCE® platform exemplifies how this breakthrough can be applied to a diverse range of targets,, including antigens, virus-like particles (VLPs), and proteins including metabolic labelling.
We present our vision of an end-to-end solution for epidemic and pandemic preparedness using the ALiCE® platform, a strategy we are currently exploring through a CEPI funded program. This approach has the potential to revolutionize rapid response capabilities for global health crises.
The CCX cell line, a novel avian substrate for efficient virus/vector production
Afternoon Exhibition & Networking Break
Join us in the exhibition hall for:1-2-1 partnering, refreshments,
COVID & Beyond Track Chair
Securing the supply chain for novel mRNA vaccine delivery systems in the future
Due to their quick development and ease of modifying the antigen, RNA vaccines play an important role in epidemic outbreaks. However, current RNA vaccine technologies can cause adverse events and may give short-lived protection, in addition to not being suitable for all types of pathogens. Changes to the delivery platform can potentially change the immune fingerprint of the vaccine through self-adjuvancy, improve the safety profile of the vaccine and increase the duration of protection. Specifically, this can be achieved through addition of immunostimulants to the formulation, through amended biodistribution and cell-targeting properties, and through optimizing stability and tissue distribution of the vehicle, respectively. At the talk, it will be presented how these concepts can be supported by the lipids offered by Avanti Research and Croda Pharma.
Pre-clinical and clinical development, mechanisms and predictive biomarkers, of vaccines and monoclonal antibodies for opioid use disorders and overdose
Pre-Clinical Development Track Chair
AI-enabled immune-profiling for accelerated vaccine development
Immune Profiling Track Chair
NanoVax™ Intranasal Adjuvant Clinical Development Update: Safety and Immunogenicity
Technology Showcases Track Chair
Diverse Applications of Vero Cells for Viral Vaccines and Viral Vectors in Chemically Defined Conditions
Formulation & Bioprocess Track Chair
AMR & Bacterial Vaccines Track Chair
The African Genome: Crafting Vaccines for a Diverse Continent
Oral Covid Vaccine - Clinical Update from phase 1 to phase 2B
Saponin Adjuvants: Challenges and Opportunities
Vaccines as an alternative to antimicrobials in animals
- Current landscape of antimicrobial use in animals
- What are our alternatives: Vaccines, Phages, etc.
- Can vaccination be a cost-effective solution?
- Financing models and incentives to develop and use alternatives to antimicrobials
- How to encourage the use of alternatives to antibiotics in livestock and aquaculture?
Persistent & Emerging Challenges in COVID-19: Outstanding Questions about Long COVID & Beyond
- COVID-19 vaccine landscape & public health impact
- Long COVID: definition, diagnosis & challenges
- Vaccine effectiveness & emerging COVID research
- Regulatory & funding challenges for COVID & Beyond
- Future Directions in COVID-19 research & policy
High-accuracy synthesis of complex long DNA templates with Ribbon Bio's algorithm-driven platform
Technological advances have created exciting opportunities across various fields of synthetic biology. However, a key challenge and bottleneck in many areas is the availability of synthetic, high accuracy long DNA molecules of high sequence complexity. While established technologies effectively meet the demand of short oligonucleotides at scale, producing multi-kbp DNA molecules remain a challenge. Ribbon Bio addresses this limitation with its proprietary DNA synthesis platform, demonstrating the successful assembly of linear DNA molecules >10kbp in length, with high sequence accuracy and complexity, which conventional synthesis technologies cannot achieve. Examples and results for these challenging DNA assemblies, particularly in vaccine discovery research will be discussed.
Combining Microneedle Patch Delivery with the Shigella flexneri 2a GMMA vaccine
AI-designed vaccine based on mRNA technology that protects against a broad range of betacoronaviruses
Regulatory Guidelines and Standards for Vaccine Safety Assessment
Antigens Derived From Microorganisms Showing Molecular Mimicry Of Tumor Associated Antigens
Vaccine responses in the elderly population
The Future of Injectables: A Vaccine through BFS Manufacturing is Possible
Can uptake keep up with the speed of vaccine developments?
- Closing the uptake gap between child and adult immunisation
- Current uptake issues: why is measles coming back and what can we do?
- The importance of RWE, data & management in immunisation programmes
- With 100+ vaccines in the pipeline; what are the realities for uptake and implementation?
- Case studies from countries with high uptake of seasonal vaccines
Off-Site Networking Drinks
Join us at the Museu Nacional d'Art de Catalunya for stunning terrace views
Create your personal agenda –check the favourite icon
Turning Target to Treatment: What Is The Pathway From A Priority Pathogen List To Vaccines?
- What are our most challenging and urgent vaccine targets?
- Which of our most stubborn targets with unmet R&D needs pose a great global threat?
- How do we prioritise development to balance the threat of viral diseases and antibiotic overconsumption with the urgency of addressing highly resistant bacterial infections?
- How can we best align these efforts with our global priorities and the pandemic accord?
- Priorities & considerations for developing vaccines: pandemic & endemic
Introducing the WHO Pandemic and Endemic pathogen lists, followed by panel:
From Zika to Zoonotic A: Anticipating and Combating Climate-Accelerated Infectious Diseases
- Surveillance of how climate change is driving changes in disease dynamics, distribution and spill over events.
- Highlighting the importance of a one-health approach
- Sustainable financing systems
- Policy and partnership strategies to strengthen our responses
- Exploring where we can adapt current vaccines to address climate-driven changes in pathogens and where novel vaccines will be needed to target emerging climate-sensitive diseases
Expo & Networking Break
Join us in the exhibition hall for:1-2-1 partnering, refreshments,
AMR & Bacterial Vaccines Track Chair
Where are we with current TB vaccine efforts?
- Predicted the impact of novel vaccines on disease burden and AMR
- Including AMR surveillance during TB Vaccine trials
- Reaching communities most effect by TB, are we considering cost and delivery?
Assay Development Advancements in Human Metapneumovirus (hMPV) Vaccine Research
Emerging & Infectious Diseases Track Chair
sa-mRNA Covid Vaccine
Clinical Trials Track Chair
Enabling early strategic decisions with Human Challenge Studies: Effectiveness of a CHIM model, the way forward
Computationally designed Pan-subtype Influenza Vaccines for human and animal disease threats
One Health & Veterinary Track Chair
Bioprocess & Manufacturing Track Chair
Transforming Vaccine Development and Manufacturing: Integrating Technology and Accessibility for a Healthier 21st Century
In the past century, vaccination has played a pivotal role in reducing mortality and morbidity caused by infectious diseases. Leveraging innovations from emerging technologies, vaccines are poised to meet evolving demands of a 21st-century society characterized by increased life expectancy, the emergency of new infections, and persistent poverty in low-income countries. Consequently, next-generation vaccines must be more effective, safer, and better tolerated across all ages, especially for children, the elderly, and other populations with compromised immune systems. Moreover, vaccine access and equality remain problematic in low- and middle-income countries (LMICs). Addressing this long-standing issue will require affordable vaccine supplies and local manufacturing capabilities. As a world-leading CRDMO, we will present how we get prepared and enable our clients, whether multinational corporations or biotech startups, to tackle these challenges. It includes comprehensive efforts to support structure-based immunogen design, accelerate novel vaccine development, enhance adjuvant accessibility and screening, and enable low-cost small-footprint manufacturing. Ultimately, the end-to-end platform aims to empower next-generation vaccine development, foster global collaboration, and support efforts in areas critical for epidemic and pandemic preparedness.
Cutaneous jet injection of naked mRNA for safe and effective vaccination against infectious diseases
The Underestimated Burden of Respiratory Syncytial Virus Disease among Older Adults: A Case for a Prevention-First Strategy
Vaccines Assessment: different approaches on serological assays
Challenges of universal flu & coronavirus vaccines
Oral norovirus vaccine induces cross-reactivity and protection against infection in humans
Avian influenza: A case study for vaccinating livestock
- The impact of vaccination on managing disease outbreaks - what have we learnt from French programs?
- The economic impact of vaccination on trade
- Matching our vaccines to the circulating strains
- Monitoring disease epidemiology and spill over to mammals, will this be the next human pandemic?
- Does livestock vaccination protect human health?
Case study of IDT Biologikas iCELLis 500 Platform: A successful scale up for vaccine and CGT manufacturing
A quadrivalent mRNA-lipid nanoparticle vaccine broadly protects against diverse Orthopoxviruses
Clinical Development of MTBVAC, a live attenuated MTb vaccine
Evaluating The Role of Controlled Human Infection Models in Vaccine Licensure
Update on Ph3 E.coli/ExPEC vaccine
AI-based target discovery for infectious disease vaccines
Preclinical and clinical evaluation of a novel RSV B-based prefusion stabilized F protein vaccine candidate
C1 Technology: Redefining Biomanufacturing for a Healthier Tomorrow- Accelerating the Scalable, Cost-Effective Production & Release of Antigens, Antibodies & Enzymes
Preclinical evaluation of a S. aureus vaccine candidate using a minipig surgical site infection model
Staphylococcus aureus is one of the most common causes of death due to bacterial infections. In the current environment of increasing antimicrobial resistance, preventative strategies are urgently needed. No successful S. aureus vaccine has been developed to date, probably due to lack of inclusion of staphylococcal immune evasion virulence factors in vaccine formulations and the use of poorly representative mouse models. To assess new S. aureus vaccine candidates, we developed a Staphylococcal minipig surgical site model based on the close homogeny between the immune systems and the skin of humans and pigs. Our candidate vaccine targets two immune evasion mechanisms of S. aureus combined with an adjuvant. The candidate vaccine significantly reduced the bacterial load in minipig surgical site infection model. Our study presents a new strategy to develop a S. aureus vaccine by way of including critical immune evasion factors, the addition of a potent adjuvant, and by using a minipig challenge model.
Reducing Flavivirus Vaccine-Induced Immunological Cross-Reactivity
Flaviviruses, such as dengue, Zika, West Nile or Yellow Fever viruses, are vector-borne pathogens of increasing global importance. Due to their structural similarity, vaccination against or infection with one flavivirus may induce immune responses that cross-react with responses to a heterologous flavivirus. As a consequence, disease enhancement of secondary flavivirus infections has been reported, a significant challenge for the development of flavivirus vaccines. The presentation will introduce the problem of antibody-enhancement in secondary flavivirus infections and will present strategies to mitigate the risk of vaccine-induced disease enhancement by designing novel antigens for safe and efficient flavivirus vaccines.
Clinical Update of OVX836, a Novel Broad-Spectrum Type A Influenza Vaccine Candidate
Expo & Networking Break
Join us in the exhibition hall for:1-2-1 partnering, refreshments, start-up pitches & poster sessions
From access to implementation: policy approaches to public health pathways to prevent respiratory illnesses in infants
Unlocking the Power of Real-World Data (RWD) and Real-World Evidence (RWE) in Vaccine Development: A Comprehensive Approach to RWE Across the Lifecycle
- Explore the diverse types of RWE that can effectively support vaccine development
- Provide insights into planning for the collection of RWD throughout vaccine development
- Discuss opportunities to leverage RWD within clinical trials
- Share examples of uses of RWE from early stage through post-marketing
Identifying challenges and opportunities in planning for RWE generation during vaccine development
Poster Presentations
Deadline for submission: Monday 7th October 2024
AMR & Bacterial Vaccines Track Chair
Progress towards a Four-Component GMMA-Based Vaccine against Shigella
A Novel, Single-dose, Live, Attenuated, Minimally Replicating Mpox Vaccine
Emerging & Infectious Diseases Track Chair
Using challenge studies to eliminate the problem of low virus circulation or strain evolution in vaccine efficacy testing
Clinical Trials Track Chair
Pragmatic & Emerging Strategies to Drive Efficiency in Large Phase III Vaccine Trials
Highly pathogenic avian influenza - the deadly hitchhiker around the Globe
One Health & Veterinary Track Chair
Bioprocess & Manufacturing Track Chair
Vaccine formulation for needle-free delivery via microneedle array patches
Novel Mucosal Approaches in Bacterial Vaccine Development: Klebsiella Nasal Vaccine and Oral Strategies for ETEC and Polio
Navigating CMC Challenges in Current Vaccine Development
A Novel Vaccine Against Neisseria Gonorrhoeae
IAVI’s Lassa vaccine development: Conducting clinical trials in West Africa
Potent And Differentiated Bivalent RSV Vaccine In Older Adults
Overcoming challenges with maternal vaccine trials
- Delivery of vaccines prior to, or during pregnancy provides benefits to the pregnant women, developing fetus and the newborn infant
- While vaccinations during pregnancy provide benefits, hesitancy continues from both the pregnant women and partner, which also impacts enrollment for maternal trials
- Maternal vaccine studies have many unique challenges with considering the health of both the pregnant women and the baby
Universal Influenza Vaccines: Leveraging One Health and Computational Innovation for Pandemic Prevention
Vaccine progress towards Group A Strep
Vaccination in pregnancy: COVID-19 vaccine
Advanced Analytical Methods to Streamline Process Development for viral-based vaccines
The pharmaceutical industry relies heavily on advanced analytical techniques to streamline drug discovery and manufacturing processes. The careful selection and planning of these techniques are crucial for product development, regulatory compliance, and overall efficiency.
In this scenario, ADVAXIA Biologics, a cGMP Contract Development and Manufacturing Organization (CDMO), exemplifies how analytical methods optimization can significantly enhance and accelerate drug development from preclinical to clinical phases.
This case study will explore the pivotal role of developing and applying advanced analytical methods in pharmaceutical manufacturing, focusing on ADVAXIA Biologics' practices in GMP-enabling activities for a viral-based vaccine.
By developing, validating, and applying these methods, ADVAXIA Biologics has enhanced its production process understanding, improved product quality, ensured regulatory compliance, and increased operational efficiency.
This comprehensive approach highlights the critical role that analytical advancements play in the success of biopharmaceutical manufacturing and the overall drug development process.
Intranasal Immunization: Device and Formulation Promises and Challenges
The case for T cell antigens in vaccines
Clesrovimab Long-Acting Antibody for the Prevention of RSV Disease in Infants: Results from the Pivotal Phase 2b/3 Studies
Factors and strategies impacting recruitment and retention in vaccine trials
Strategies for Developing Bacterial Vaccines in a One Health Framework
Introduction of Commercially Relevant, Ready to Use, High Value Vaccine Adjuvant Systems
Unlocking targeted medicines with a transformative ‘Multi Organ Protective’ (“MOP”) mRNA platform - Targeted & adjuvanted mRNA vaccine
Infection models to test the efficacy of vector born virus vaccines: RVF and BT as examples
Thermostable cRNA-VLP and VLP Vaccine using the D-Crypt™ Platform: Revolutionizing Vaccine Production and Delivery
The Role of Vaccines & mAbs in Neonatal Sepsis Prevention
Post-authorization safety and effectiveness evaluation of vaccines deployed under emergency use authorization
- Diseases (e.g. Ebola, Malaria, Dengue) that are associated with outbreaks and are not established as endemically with vaccines that have/are being developed
- How should the global health community consider evaluation of these vaccines outside of clinical trials leading to EUA?
Update on Novavax Investigational Influenza vaccine and COVID-19-INFLUENZA Combination Vaccine Development
The power of partnerships in addressing diversity targets & enabling the focus of research to where it is most needed
Monoliths as an Effective Tool in Vaccine Production – Showcases of Fast and Efficient Virus Purification
Metavac®-RSV: in vivo Proof of Concept of first Intranasal vaccine against RSV and HMPV
Efficacy and Immunogenicity Results of Messenger RNA Influenza Vaccine in Adults 18−64 Years of Age
Introduction
Messenger RNA vaccines have demonstrated efficacy in protection against COVID-19. The speed and flexibility of the platform lends itself well to influenza, where the virus is constantly evolving and there remains an unmet need for better influenza vaccines. Pfizer has developed a quadrivalent mRNA vaccine targeting influenza, qIRV.
Methods
Pfizer conducted a Phase 3, randomized, observer-blinded study to evaluate the safety, tolerability, immunogenicity, and efficacy of qIRV compared to a licensed influenza vaccine (QIV) against laboratory-confirmed (RT-PCR) influenza (LCI) in healthy adults 18 years and older (stratified by age: 18 through 64 and ≥65 years). Participants 18–64-years were enrolled during the 2022–2023 northern hemisphere influenza season. Immunogenicity was evaluated by hemagglutination inhibition (HAI) assay and quantification of hemagglutinin-specific CD4+ and CD8+ T cells. Reactogenicity was collected by eDiary in a subset population and other adverse events were collected from all participants.
Results
The primary analysis of relative vaccine efficacy (RVE) of qIRV versus QIV in participants 18 through 64 years of age was performed based on 144 total LCI cases as of 17 Mar 2023. RVE in the evaluable efficacy population was 34.5% (95% CI 7.4-53.9) which met both non-inferiority (NI) and superiority criteria. The LCI cases included A/H3N2 and A/H1N1 strains. NI of HAI antibody responses was shown for influenza A strains but not influenza B. IFNγ+ CD4+ T-cell and CD8+ T-cell GMFRs were higher in the qIRV group for all 4 strains. Primarily mild or moderate reactogenicity was observed in both vaccine groups but reported more frequently among qIRV recipients. AE profile was similar between both vaccine groups.
Conclusions
qIRV is the first mRNA vaccine to demonstrate efficacy in prevention of influenza. Lack of influenza B cases limits confirmation of efficacy against both influenza A and B strains. qIRV has an acceptable safety profile.
Innovations in Vet Vaccines: Bridging Animal and Human Health through One Health Approaches
Development, Scale-Up, and Manufacture of an Oncolytic Virus Vaccine
Navigating the CMC Pathway: Lovaltech’s Journey from Lab Bench to Clinical-Grade Nasal Vaccine
Expo & Networking Break
Join us in the exhibition hall for:1-2-1 partnering, refreshments
The Evolving Definition of Protection: Progress and Prospects in Therapeutic Vaccines & Immune Modulation
- The evolving landscape of what constitutes a vaccine; exploring therapeutic vaccines and the distinction between prophylactic and therapeutic approaches
- How well do we understand the immune system to be able to manipulate it for therapeutic uses?
- Updates on therapeutic vaccine development
- Future prospects for therapeutic vaccines & immune modulation
Senior Representative, BioNTech - TBC
Evening Networking Drinks
Join us in the Exhibition Hall for networking drinks
Create your personal agenda –check the favourite icon
Expo & Networking Break
Join us in the exhibition hall for 1-2-1 partnering
Clinical Trials Track Chair
Optimizing product development for infectious diseases - using controlled human infection models
Bolstering the Development of Neglected Disease Vaccines
Neglected Diseases & Global Health Track Chair
Panel: Defining Vaccine Value: Evaluating Early-Stage Value and Ensuring Corporate Security
- Approaches used to define potential value of an early stage candidate; technology, safety profile
- Impact of product area in value; cancer, priority pathogens
- Strategies for protecting IP and navigating corporate security challenges to safeguarding innovations
Partnerships & Access Track Chair
Supply & Logistics Track Chair
The Source of Saponin Adjuvants: QS21 - Approved, Available, and Abundant
Manufacturing Technologies Track Chair
New Technologies for Flu Vaccines. Better Vaccines?
Cancer & Therapeutic Vaccines Track Chair
EVX-01 Personalized Neoantigen Vaccine: One-Year Insights from a Phase 2 Cancer Study
Transforming Vaccine Logistics: GSK’s Cold Chain Solutions through Serialization, Automation and Green Responsibility
High-Throughput, Multiplexed Analysis of HA and NA Content Across All Influenza Vaccine Production Platforms
Real World Evidence - From Safety to a Potential Tool for Advancing New Medical Therapies and Patient Health Outcomes
A personalized vaccine platform technology for cancer and infectious disease
TheraPHIX™ technology for ambient temperature liquid-stable mRNA-LNP therapeutics and vaccines
Microarray Patches: Current interests and the road ahead
CAMYO-01: colorectal cancer-specific camyotypes formulated into an mRNA vaccine
- Aberrant shared translation events in cancer cells lead to novel dark tumor shared antigens
- Shown to be highly presented, highly immunogenic, and capable of inducing tumor regression
- In parallel to the lead CAMYO program in CRC, other indications have shown a similar set of camyotope targets, leading to the buildout of a large antigen library across tumor indications
ARVAC: Phase III results from an adapted recombinant booster vaccine against SARS-CoV-2
Vaccine manufacturing modelling to support strategic pandemic preparedness
Rapid Vaccine Solutions: Selecting Australia as a Location for Vaccine Clinical Trials
Vaccines for a sustainable planet: Insights from Palio
Why are public private partnerships so important for vaccine development and how do we sustain them?
From Formulation to Function: Closing Current Gaps in Microarray Development
FiCAT, A Next Generation Gene Writing Platform for Advanced Therapies.
Setting the Record Straight: Uniformity in Vaccine Clinical Trials Across Brick-and-Mortar and Mobile Research Sites
Learn how mobile sites adhere to the same rules and regulations as B&M sites.
Addressing Misconceptions about Mobile Sites: Mobile research sites are not limited in scope; they offer the same high-quality care and research capabilities as traditional sites, expanding access to underrepresented populations.
Clinical Trial Performance: Mobile sites enhance clinical trial performance by reaching diverse patient populations, improving recruitment and retention rates, and accelerating study timelines without compromising data integrity.
Centralized Infrastructure: A robust centralized infrastructure supports mobile sites by ensuring seamless coordination, consistent data management, and adherence to regulatory standards across all locations, boosting trial efficiency.
A strategy blueprint to combat the superbug Neisseria gonorrhoeae
Vaccine Correlation using Tasso Capillary Device
New saponin-containing adjuvants for Global Health
Optimize Pipette Accuracy in just 3 minutes
BioNTech’s oncology pipeline: combining cancer vaccines with immunomodulators & targeted therapies
Expo & Networking Break
Join us in the exhibition hall for:
1-2-1 partnering & poster sessions
Clinical Trials Track Chair
Predictors of vaccine efficacy: identifying correlates of protection to support vaccine development
A second-generation vaccine for malaria
Neglected Diseases & Global Health Track Chair
Partnerships & Access Track Chair
Vaccine Pipeline: evolving trends & new areas of focus
§ Overview of emerging trends in vaccine development.
§ The role of vaccine innovation in addressing a wide range of health challenges, such as health emergencies, antimicrobial resistance, or dangers posed by climate change and demographic changes.
Reliance Opportunities for Vaccines: Sharing Practices including AMA Pilot Experience
In this session, we will explore opportunities of reliance for vaccines supporting regulatory authorities’ decision-making based on information submitted and approved by high surveillance agencies. The collaboration among regulators reduces duplication of efforts at agency and industry level accelerating patients access to medicines, particularly, vaccines. Practices on post-approval and pre-approval space will be shared with focus on a recent pilot with the African Medicines Agency (AMA), which aims to establish a harmonized regulatory framework for medicines in Africa.
Supply & Logistics Track Chair
Global Implications of the BIOSECURE Act
- What global efforts are being made to integrate and ensure global manufacturing capacity?
- Will the EU follow suit and implement similar policies?
Manufacturing Technologies Track Chair
Combining Precision ImmunomicsTM tumour target discovery with optimised vaccine design
Advancing Malaria Vaccine Development: Public-Private Partnerships, Novel Technologies, and Multistage Strategies
- Current strategies for developing the next-generation malaria vaccines
- What exciting prospects do novel technologies present for advancing malaria vaccine development, especially multistage vaccines?
- Accelerating malaria vaccine development through public-private partnerships
Generating clinical immunogenicity data for use in decision-making and licensure
Sustaining Access Today: The Need for Delivery Innovation at the Last Mile in all Countries
In the "post pandemic" world, access has become an "all country" issue as both high- and low-income settings still find themselves challenged by vaccine delivery for outbreaks like Mpox and routine vaccination. ApiJect is looking to address these challenges with innovative approaches to delivery that finally solve last mile challenges and open up markets in an environmentally sustainable way. This presentation will summarize the key elements to some of those approaches and device programs.
Strategies for large scale vaccinations for the world – multidose vial and CMC challenges
Targeting multiple neoantigens in personalized cancer vaccines
Compliance in supply chain & logistics operations: make or break your clinical trial.
Tolerability and Immunogenicity of Amezosvatein, a New Recombinant Herpes Zoster Vaccine with a Novel Adjuvant
Funding Pathways: Navigating Government Funding and Non-Diluted Strategies for Biotechs and Biopharmas
Advancing Vaccine Access and Localization in Africa: Strategies for Sustainable Development and Partnership
Neomatrix: an innovative fully-synthetic DNA platform for next generation Cancer Vaccines.
Bridging Gaps in Global Health: Building a Sustainable Vaccine Production Ecosystem in Latin America
- What type of manufacturing capabilities need to be established to take ownership of vaccine production and distribution within the region?
- Adopting and innovating new tech to enhance self-reliance and reduce dependency on global supply chains
- The importance of strategic regional partnerships; addressing challenges in knowledge transfer, and building sustainable local expertise in vaccine production
- Strategies for creating a sustainable and resilient vaccine manufacturing ecosystem
- Examination of the regulatory frameworks governing vaccine manufacturing in LATAM; Challenges in harmonizing regulations across the region to streamline manufacturing processes
Panel: Enhancing Vaccine Distribution and Supply Chain Resilience Post-Pandemic
- Advances in thermostability and alternative delivery to reduce the need for cold chain; inequities of cold chain infrastructure and vaccine distribution
- What strategies are being employed to secure vaccine supply chains and technologies?
- Managing supply chains and manufacturing processes in the current global landscape.
- Policy changes & implications on vaccine distribution and supply chain security
The Vaccine Innovation Pathway: The UK’s First Clinical Trial Delivery Accelerator
From policy to practice: navigating the COVID-19 vaccination landscape in Europe
Applying Analytical Technologies to Support Process Development
Expo & Networking Break
Join us in the exhibition hall for:
1-2-1 partnering
Will AI Define Tomorrow's Vaccines? Insights into Tech-driven Innovations
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events